ATE546136T1 - Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln - Google Patents

Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln

Info

Publication number
ATE546136T1
ATE546136T1 AT03774657T AT03774657T ATE546136T1 AT E546136 T1 ATE546136 T1 AT E546136T1 AT 03774657 T AT03774657 T AT 03774657T AT 03774657 T AT03774657 T AT 03774657T AT E546136 T1 ATE546136 T1 AT E546136T1
Authority
AT
Austria
Prior art keywords
cardioprotection
neuroprotection
procedures
intravenous administration
volatile anesthetic
Prior art date
Application number
AT03774657T
Other languages
English (en)
Inventor
Raul Trillo
Ralph Lessor
Satish Pejaver
Navneet Puri
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Application granted granted Critical
Publication of ATE546136T1 publication Critical patent/ATE546136T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03774657T 2002-10-11 2003-10-09 Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln ATE546136T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41793402P 2002-10-11 2002-10-11
PCT/US2003/031826 WO2004032858A2 (en) 2002-10-11 2003-10-09 Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics

Publications (1)

Publication Number Publication Date
ATE546136T1 true ATE546136T1 (de) 2012-03-15

Family

ID=32094122

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03774657T ATE546136T1 (de) 2002-10-11 2003-10-09 Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln

Country Status (19)

Country Link
US (1) US7999011B2 (de)
EP (1) EP1558226B1 (de)
JP (1) JP5210486B2 (de)
KR (2) KR101403264B1 (de)
CN (2) CN102283821A (de)
AT (1) ATE546136T1 (de)
AU (1) AU2003282464B2 (de)
BR (1) BR0314617A (de)
CA (1) CA2500310C (de)
DK (1) DK1558226T3 (de)
ES (1) ES2382911T3 (de)
HK (1) HK1079703A1 (de)
IL (1) IL167472A (de)
MX (1) MXPA05003741A (de)
NZ (1) NZ539298A (de)
PL (1) PL219493B1 (de)
RU (1) RU2350323C2 (de)
WO (1) WO2004032858A2 (de)
ZA (1) ZA200502741B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
CN101014364B (zh) 2002-12-24 2012-01-18 里纳特神经系统学公司 抗ngf抗体及其使用方法
US20080119820A1 (en) * 2006-09-20 2008-05-22 Phan Phillip C Methods for Delivering Volatile Anesthetics for Regional Anesthesia and/or Pain Relief
GB0619499D0 (en) 2006-10-03 2006-11-08 Lucent Technologies Inc Encrypted data in a wireless telecommunications system
WO2009059989A1 (de) * 2007-11-06 2009-05-14 B. Braun Melsungen Ag Einen hydrophoben wirkstoff enthaltende wässrige emulsionen
ES2765007T3 (es) * 2008-01-22 2020-06-05 Univ Texas Composiciones anestésicas volátiles y métodos de uso
US9675544B2 (en) * 2008-01-22 2017-06-13 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
AU2015200210B2 (en) * 2008-01-22 2016-08-11 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
CA2760775C (en) * 2009-05-05 2019-03-05 Vapogenix, Inc. Novel formulations of volatile anesthetics and methods of use for reducing inflammation
US20120219596A1 (en) 2009-07-30 2012-08-30 Wendelin Stark Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
RU2408396C1 (ru) * 2009-07-30 2011-01-10 Государственное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия Федерального агентства по здравоохранению и федеральному развитию" Комбинированная двухсегментарная регионарная анестезия при выполнении каротидной эндартерэктомии у больных критической ишемией нижних конечностей и выраженным болевым синдромом
FR2956323B1 (fr) * 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
WO2012177840A1 (en) * 2011-06-24 2012-12-27 Vapogenix, Inc. Novel formulations and methods for treating dermatological disorders or diseases
CN105611921A (zh) * 2013-03-15 2016-05-25 维普詹尼克斯公司 新型镇痛组合物
ITMO20130075A1 (it) 2013-03-22 2014-09-23 Enrico Giuliani Dispositivo di somministrazione

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1018773A (en) * 1962-09-13 1966-02-02 Bellon Labor Sa Roger ª‡-phenyl-ª‰-2-furyl-propionitrile derivatives
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US5628930A (en) 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US5635538A (en) 1993-03-16 1997-06-03 Alliance Pharmaceutical Corp. Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
JP2961034B2 (ja) * 1993-09-16 1999-10-12 アルプス電気株式会社 磁気ヘッド
ATE211135T1 (de) * 1993-09-24 2002-01-15 Univ British Columbia Aminocyclohexylester und ihre anwendung
FR2726267B1 (fr) * 1994-10-26 1998-01-02 Smithkline Beecham Lab Nouveaux agents anti-arythmiques, compositions pharmaceutiques les contenant, et procede pour les preparer
GB2350297A (en) 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
EP1311270B1 (de) 2000-07-26 2008-01-09 Taro Pharmaceutical Industries Limited Nicht-sedierende barbituratverbindungen als neuroprotektive wirkstoffe

Also Published As

Publication number Publication date
CA2500310A1 (en) 2004-04-22
AU2003282464A1 (en) 2004-05-04
RU2005114008A (ru) 2005-10-27
PL376217A1 (en) 2005-12-27
AU2003282464B2 (en) 2010-02-25
KR20050056230A (ko) 2005-06-14
US7999011B2 (en) 2011-08-16
EP1558226A2 (de) 2005-08-03
KR101403264B1 (ko) 2014-06-02
PL219493B1 (pl) 2015-05-29
CN102283821A (zh) 2011-12-21
BR0314617A (pt) 2005-08-02
KR20120030598A (ko) 2012-03-28
NZ539298A (en) 2008-11-28
HK1079703A1 (zh) 2006-04-13
WO2004032858A3 (en) 2004-09-23
US20040127578A1 (en) 2004-07-01
JP2006504740A (ja) 2006-02-09
CA2500310C (en) 2013-03-12
CN1703209A (zh) 2005-11-30
RU2350323C2 (ru) 2009-03-27
DK1558226T3 (da) 2012-05-07
IL167472A (en) 2013-10-31
JP5210486B2 (ja) 2013-06-12
MXPA05003741A (es) 2005-06-17
ZA200502741B (en) 2006-02-22
EP1558226B1 (de) 2012-02-22
EP1558226A4 (de) 2008-04-02
ES2382911T3 (es) 2012-06-14
WO2004032858A2 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
ATE546136T1 (de) Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln
JP2006501240A5 (de)
BRPI0406667A (pt) Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg
Meechan et al. The use of patient-controlled transcutaneous electronic nerve stimulation (TENS) to decrease the discomfort of regional anaesthesia in dentistry: A randomised controlled clinical trial
BR0315573A (pt) Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica
Jayakaran et al. Local anesthetics in pediatric dental practice
Younis et al. Taking the'ouch'out-effect of buffering commercial xylocaine on infiltration and procedure pain-a prospective, randomised, double-blind, controlled trial
Gupta et al. “Sodium bicarbonate”: an adjunct to painless palatal anesthesia
Kulkarni et al. Painless anaesthesia in pediatric dentistry: an updated review
Barker et al. Femoral nerve blockade administered preclinically for pain relief in severe knee trauma is more feasible and effective than intravenous metamizole: a randomized controlled trial
KR900701309A (ko) 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법
EA200600284A1 (ru) Дооперационное лечение послеоперационной боли
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
Buhse Efficacy of EMLA cream to reduce fear and pain associated with interferon beta-1a injection in patients with multiple sclerosis
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
UA27230C2 (uk) Похідні андростану, заміщені по 16-му положенню четвертинною амонієвою групою, для використання як нервово-м'язових блокаторів та фармацевтична композиція, що здатна викликати нервово-м'язову блокаду
ATE446309T1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung
Neill Postoperative analgesia following brachial plexus block
AU2012244095A1 (en) Method for the non-surgical treatment of lipodystrophy in a retrovirus-infected individual
Padmanabhan et al. Dental Anesthesia: Can Needle-Free Injections Help
EA200600757A1 (ru) Тетрапептид, регулирующий уровень глюкозы в крови при сахарном диабете
RU2177303C2 (ru) Способ лечения ортопедических больных периартикулярным введением препарата
Yaacob et al. The efficacy of xylocaine topical anaesthetic in reducing injection pain
COŞAR et al. Pain control following lumbar laminectomy: Comparison of epidural morphine and morphine plus bupivacaine
Arangannal et al. Intranasal Local Anaesthesia: A Recent Advancement in Pediatric Dentistry.